Quemliclustat
Small molecule
Evidence outlook · registrational
Pancreatic Ductal Adenocarcinoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2030-11-30.
Company guidance: data expected first half of 2027 (Arcus Biosciences, 5 May 2026). “Results from this study are expected in the first half of 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PRISM-1 NCT06608927 · Pancreatic Ductal Adenocarcinoma Registry: NCT06608927 | 3 | Overall Survival (OS) (Up to 72 months) 2030-11-30 | In progress: results expected 30 Nov 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Quemliclustat: this drug | Phase 3 | Small molecule | CD73 (NT5E) | not yet graded | No reviewed efficacy summary in this indication | |
| Daraxonrasib (Rasonque) | Approved | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| INCB161734 | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Setidegrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Navlimetostat | Phase 2/3 | Small molecule | PRMT5 (protein arginine methyltransferase 5), MTA-cooperative binding | not yet graded | No reviewed efficacy summary in this indication | |
| Autogene Cevumeran | Phase 2 | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| ERAS-0015 | Phase 2 | Small molecule | pan-RAS | not yet graded | No reviewed efficacy summary in this indication | |
| GFH375 | Phase 2 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Nuzefatide Pevedotin | Phase 2 | Peptide | EphA2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARV-806 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Vopimetostat | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Quemliclustat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.